Rydel J J, Korbet S M, Borok R Z, Schwartz M M
Department of Medicine, Rush Presbyterian St Lukes Medical Center, Chicago, IL, USA.
Am J Kidney Dis. 1995 Apr;25(4):534-42. doi: 10.1016/0272-6386(95)90120-5.
The authors performed a retrospective clinicopathologic study in 81 patients with primary focal segmental glomerular sclerosis (FSGS) to determine whether they could identify clinical or histologic features at presentation that could be predictive of outcome and response to therapy. Males constituted 58% of patients, and 53% were black. At biopsy the patients were 40 +/- 17 years old; 74% were nephrotic, and renal insufficiency was present in 62%. The average time from presentation to biopsy was 16 months, and the average total follow-up was 62 months. Nephrotic patients had a significantly poorer prognosis as compared with nonnephrotic patients (5- and 10-year survivals of 76% and 57% v 92% and 92%; P < 0.05). A multivariate analysis was done on histologic and clinical features at biopsy, assessing for risk factors leading to end-stage renal disease, showing only the serum creatinine and the degree of interstitial fibrosis to have a significant correlation. Thirty nephrotic patients received prednisone, with a treatment time of 5.5 +/- 4 months and a total dose of 5.9 +/- 2.9 g per course of treatment. Fifteen of these patients (50%) achieved a remission by 3.7 +/- 2 months (10 complete remission and 5 partial remissions), with all patients responding within 9 months. Only two patients had spontaneous remissions (both partial). The 5- and 10-year survival for patients in remission were both 100% as compared with 66% and 41% (P < 0.01), respectively, for nephrotic patients not in remission. No clinical feature at presentation of biopsy was predictive of response to therapy when a multivariate analysis was performed.(ABSTRACT TRUNCATED AT 250 WORDS)
作者对81例原发性局灶节段性肾小球硬化(FSGS)患者进行了一项回顾性临床病理研究,以确定他们能否识别出就诊时可预测预后及治疗反应的临床或组织学特征。患者中男性占58%,53%为黑人。活检时患者年龄为40±17岁;74%为肾病综合征患者,62%存在肾功能不全。从就诊到活检的平均时间为16个月,平均总随访时间为62个月。与非肾病综合征患者相比,肾病综合征患者的预后明显较差(5年和10年生存率分别为76%和57%,而非肾病综合征患者为92%和92%;P<0.05)。对活检时的组织学和临床特征进行了多因素分析,评估导致终末期肾病的危险因素,结果显示只有血清肌酐和间质纤维化程度有显著相关性。30例肾病综合征患者接受了泼尼松治疗,治疗时间为5.5±4个月,每疗程总剂量为5.9±2.9g。其中15例患者(50%)在3.7±2个月时达到缓解(10例完全缓解,5例部分缓解),所有患者均在9个月内有反应。只有2例患者自发缓解(均为部分缓解)。缓解患者的5年和10年生存率均为100%,相比之下,未缓解的肾病综合征患者分别为66%和41%(P<0.01)。进行多因素分析时,活检就诊时的任何临床特征均不能预测治疗反应。(摘要截短至250字)